6,6-Dimethyl-heptanenitrile | 30616-89-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6,6-Dimethyl-heptanenitrile
• 英文别名: 6,6-Dimethylheptanenitrile
• CAS: 30616-89-8
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: WMFRMVOTRRSESN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,6-Dimethyl-heptanenitrile 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 1-Amino-6.6-dimethyl-heptan
  参考文献：
  名称：

  10.1002/anie.202402858

  摘要：

  AbstractThe tert‐butyl group is a common aliphatic motif extensively employed to implement steric congestion and conformational rigidity in organic and organometallic molecules. Because of the combination of a high bond dissociation energy (~100 kcal mol−1) and limited accessibility, in the absence of directing groups, neither radical nor organometallic approaches are effective for the chemical modification of tert‐butyl C−H bonds. Herein we overcome these limits by employing a highly electrophilic manganese catalyst, [Mn(CF3bpeb)(OTf)2], that operates in the strong hydrogen bond donor solvent nonafluoro‐tert‐butyl alcohol (NFTBA) and catalytically activates hydrogen peroxide to generate a powerful manganese‐oxo species that effectively oxidizes tert‐butyl C−H bonds. Leveraging on the interplay of steric, electronic, medium and torsional effects, site‐selective and product chemoselective hydroxylation of the tert‐butyl group is accomplished with broad reaction scope, delivering primary alcohols as largely dominant products in preparative yields. Late‐stage hydroxylation at tert‐butyl sites is demonstrated on 6 densely functionalized molecules of pharmaceutical interest. This work uncovers a novel disconnection approach, harnessing tert‐butyl as a potential functional group in strategic synthetic planning for complex molecular architectures.

  DOI：

  10.1002/anie.202402858
• 作为产物：
  描述：

  3,3-二甲基-1-丁烯 、 丙烯腈 生成 6,6-Dimethyl-heptanenitrile
  参考文献：
  名称：

  Giese, Bernd; Kretzschmar, Gerhard, Angewandte Chemie, 1981, vol. 93, # 11, p. 1015 - 1016

  摘要：

  DOI：

文献信息

• Kinase antagonists
  申请人：Knight A. Zachary

  公开号：US20070293516A1

  公开（公告）日：2007-12-20

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。
• Benzothiazole Kinase Inhibitors and Methods of Use
  申请人：Intellikine LLC

  公开号：US20150225407A1

  公开（公告）日：2015-08-13

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

  本发明提供了能够调节脂质激酶如PI3激酶、酪氨酸激酶和蛋白激酶如mTOR的化学实体或化合物以及其药物组合物。本发明还提供了使用这些组合物来调节这些激酶的方法，特别是用于治疗应用。
• METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS
  申请人：Wilson Troy Edward

  公开号：US20110269779A1

  公开（公告）日：2011-11-03

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

  本发明提供了能够调节特定蛋白激酶（如mTor、酪氨酸激酶和/或脂质激酶如PB激酶）在眼组织中的信号传导的化学实体或化合物以及其制药组合物。本发明还提供了利用这些组合物调节这些激酶中的一个或多个的活性的方法，特别是用于治疗应用。
• Novel Bicyclic Cannabinoids
  申请人：Makriyannis Alexandros

  公开号：US20070135388A1

  公开（公告）日：2007-06-14

  Bicyclic-cannabinoids and methods of preparation and use are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions.

  本文介绍了双环大麻素及其制备和使用方法。当以治疗有效量的这些化合物给个体或动物注射时，会在个体或动物体内产生足够高的该化合物水平，从而引起生理反应。这种生理反应可能对治疗多种生理状况有用。
• KINASE ANTAGONISTS
  申请人：KNIGHT ZACHARY A.

  公开号：US20100009963A1

  公开（公告）日：2010-01-14

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.

  本发明提供了一些新型化合物，它们是PI3激酶、PI3激酶和酪氨酸激酶、PI3激酶和mTOR、或PI3激酶、mTOR和酪氨酸激酶的拮抗剂。